



65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735
www.genvec.com

FOR IMMEDIATE RELEASE:

CONTACT:
Douglas J. Swirsky
Chief Financial Officer
(240) 632-5510
dswirsky@genvec.com

**GENVEC TO HOST FOURTH QUARTER AND YEAR-END
2007 EARNINGS CALL AND WEBCAST**

GAITHERSBURG, MD – March 7, 2008 – GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the fourth quarter and year ended December 31, 2007 on Thursday, March 13, 2008 after market close. GenVec will hold a conference call at 10:00 a.m. EST on Friday, March 14, 2008 to discuss the company's 2007 financial results and 2008 business outlook.

To listen to the live conference call, please dial 888.679.8033 (U.S. or Canada) or 617.213.4846 (international) and use access code 75946056. Participants may pre-register for the call anytime at: <https://www.theconferencingservice.com/prereg/key.process?key=PP9JYTUK8>. Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 12:00 p.m. on March 14, 2008 through March 21, 2008. To listen to the audio replay, dial 888.286.8010 (U.S. or Canada) or 617.801.6888 (international) and use access code 89348800.

A live webcast of the conference call will be available on the Company's website will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™, is currently in a pivotal clinical study (the PACT study) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

###